CN108409592A - 一种左乙拉西坦的杂质及其合成方法 - Google Patents
一种左乙拉西坦的杂质及其合成方法 Download PDFInfo
- Publication number
- CN108409592A CN108409592A CN201810468738.9A CN201810468738A CN108409592A CN 108409592 A CN108409592 A CN 108409592A CN 201810468738 A CN201810468738 A CN 201810468738A CN 108409592 A CN108409592 A CN 108409592A
- Authority
- CN
- China
- Prior art keywords
- method described
- acid
- formula
- added
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012535 impurity Substances 0.000 title abstract description 11
- 229960004002 levetiracetam Drugs 0.000 title abstract description 9
- 238000010189 synthetic method Methods 0.000 title abstract description 4
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 title abstract 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 7
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims 3
- 150000002825 nitriles Chemical class 0.000 claims 1
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- -1 acetyl pyrrole alkyl compound Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 238000004176 ammonification Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229940062717 keppra Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种式I所示的左乙拉西坦新杂质以及该杂质的合成方法，
Description
技术领域
本发明涉及一种左乙拉西坦的新杂质以及合成方法，属于医药化工领域。
背景技术
左乙拉西坦(Levetiracetam，商品名为Keppra)是由比利时公司UCB研制的一种新型的抗癫痫药物，它是一种乙酰吡咯烷类化合物，其化学名称为(S)-α-乙基-2-氧合-1-乙酰胺吡咯烷，结构如下所示：
其中式II所示的化合物α-乙基-2-氧代-1-吡咯烷乙酸为其关键中间体，例如专利US4696943报道将其通过拆分获得(S)-α-乙基-2-氧代-1-吡咯烷乙酸，再进一步氨化得到左乙拉西坦：
发明内容
发明人在研究左乙拉西坦的制备过程中发现式II所示的α-乙基-2-氧代-1-吡咯烷乙酸存在一种未曾被报道过的新杂质，该杂质可由中间体带到成品中去，对成品质量造成影响。该杂质命名为2-[(3-羧基丙基)氨基]丁酸，结构式如式I所示：
本发明还提供了式I所示化合物的制备方法，包括以下步骤：
(a)加热条件下，使式II的化合物α-乙基-2-氧代-1-吡咯烷乙酸在强碱条件下在水或者有机溶剂中反应，
(b)反应结束后，在步骤(a)的反应液中加酸，分离得到式I所示化合物，
其中所述碱优选为：氢氧化钠、氢氧化钾、甲醇钠、叔丁醇钠、叔丁醇钾或丁基锂。所述碱与式II所示化合物的投料摩尔比优选为1～20：1。
所述有机溶剂优选为：四氢呋喃、甲苯、甲基叔丁基醚或乙腈。所述水或有机溶剂体积用量相对于每克式II所示化合物优选为1.5ml～10ml。
步骤(b)所述酸优选为盐酸。
步骤(b)加入酸调节pH至0.5～5.0，进一步优选调节pH至3.0。
本发明发现的新杂质对于左乙拉西坦成品的质量控制方面具有非常有用的价值，例如：研究该杂质及其衍生物对于成品的污染程度，以及研究如何控制该杂质的生成，降低对成品污染的风险。
具体实施方式
下面结合实施例，对本发明的具体实施方式作进一步详细描述。以下实施例仅用于说明本发明，但不用于限制本发明的范围。
实例1：
取α-乙基-2-氧代-1-吡咯烷乙酸20g于三口瓶中，加入水60ml，然后加入氢氧化钠9.4g，于90～120℃下搅拌反应9小时，加入盐酸调节pH至3.0，降温析晶得到2-[(3-羧基丙基)氨基]丁酸，烘干称重得20.1g，收率为90％，纯度为95.8％。
结构鉴定如下：
MS-ESI(M+1)＝190.1；MS-ESI(M-1)＝188.1。
H-NMR(DMSO-d6):δ:12.38(S,1H),12.01(S,1H),3.43-3.37(m,1H),3.35-3.27(m,1H),2.57-2.49(m,2H),2.33-3.27(m,2H),1.75-1.60(m,4H),0.89-0.83(m,3H)。
实例2：
取α-乙基-2-氧代-1-吡咯烷乙酸20g于三口瓶中，加入四氢呋喃30ml，然后加入氢氧化钾39.4g，于90～120℃下搅拌反应8小时，浓缩掉溶剂，加入水和精制盐酸调节pH至1.0，降温析晶，过滤得到2-[(3-羧基丙基)氨基]丁酸，烘干后称重为15.3g，收率为69.2％，纯度为97.2％。
实例3：
取α-乙基-2-氧代-1-吡咯烷乙酸20g于三口瓶中，加入甲苯100ml，然后加入甲醇钠50.5g，于95～110℃下搅拌反应6小时，浓缩掉溶剂，加入水和精制盐酸调节pH至4.0，降温析晶，过滤得到2-[(3-羧基丙基)氨基]丁酸，烘干后称重为15.3g，收率为57％，纯度为93.5％。
实例4：
取α-乙基-2-氧代-1-吡咯烷乙酸20g于三口瓶中，加入甲基叔丁基醚70ml，然后加入叔丁醇钠168.4g，于50～70℃下搅拌反应9小时，浓缩掉溶剂，加入水和精制盐酸调节pH至2.0，降温析晶，过滤得到2-[(3-羧基丙基)氨基]丁酸，烘干后称重为17.3g，收率为78.3％，纯度为89.5％。
实例5：
取α-乙基-2-氧代-1-吡咯烷乙酸20g于三口瓶中，加入乙腈180ml，然后加入叔丁醇钾91.7g，于50～70℃下搅拌反应8小时，浓缩掉溶剂，加入水和精制盐酸调节pH至4.5，降温析晶，过滤得到2-[(3-羧基丙基)氨基]丁酸，烘干后称重为19.2g，收率为86.9％，纯度为92.5％。
实例6：
取α-乙基-2-氧代-1-吡咯烷乙酸20g于三口瓶中，加入四氢呋喃80ml，然后加入丁基锂142.2g，于50～70℃下搅拌反应3小时，浓缩掉溶剂，加入水和精制盐酸调节pH至3.5，降温析晶，过滤得到2-[(3-羧基丙基)氨基]丁酸，烘干后称重为17.6g，收率为80.0％，纯度为93.9％。
Claims (9)
1.一种化合物，命名为2-[(3-羧基丙基)氨基]丁酸，结构式如式I所示：
2.式I所示化合物的制备方法，包括以下步骤：
(a)加热条件下，使式II的化合物α-乙基-2-氧代-1-吡咯烷乙酸在强碱条件下在水或者有机溶剂中反应，
(b)反应结束后，在步骤(a)的反应液中加酸，分离得到式I所示化合物，
3.根据权利要求2所述的方法，其中所述碱选自：氢氧化钠、氢氧化钾、甲醇钠、叔丁醇钠、叔丁醇钾或丁基锂。
4.根据权利要求2所述的方法，所述有机溶剂选自：四氢呋喃、甲苯、甲基叔丁基醚或乙腈。
5.根据权利要求2所述的方法，所述碱与式II所示化合物的投料摩尔比为1～20：1。
6.根据权利要求2所述的方法，所述水或有机溶剂体积用量相对于每克式II所示化合物为1.5ml～10ml。
7.根据权利要求2所述的方法，步骤(b)所述酸为盐酸。
8.根据权利要求2所述的方法，步骤(b)加入酸调节pH至0.5～5.0。
9.根据权利要求8所述的方法，步骤(b)加入酸调节pH至3.0。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810468738.9A CN108409592B (zh) | 2018-05-16 | 2018-05-16 | 一种左乙拉西坦的杂质及其合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810468738.9A CN108409592B (zh) | 2018-05-16 | 2018-05-16 | 一种左乙拉西坦的杂质及其合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108409592A true CN108409592A (zh) | 2018-08-17 |
| CN108409592B CN108409592B (zh) | 2023-02-03 |
Family
ID=63139536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810468738.9A Active CN108409592B (zh) | 2018-05-16 | 2018-05-16 | 一种左乙拉西坦的杂质及其合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108409592B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11384050B1 (en) | 2021-02-03 | 2022-07-12 | Vitaworks Ip, Llc | Method for preparing levetiracetam and intermediates thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0101588A1 (en) * | 1982-08-13 | 1984-02-29 | S.I.P.C.A.M. S.p.A. Società Italiana Prodotti Chimici e per l'Agricoltura Milano | Compositions comprising amino and diamino acid derivatives and use thereof as plant growth stimulants |
| US20050070519A1 (en) * | 2001-12-19 | 2005-03-31 | Schofield Christopher Joseph | Cyclisation process for the preparation of c-2 beta-lactam compounds |
| US20060287242A1 (en) * | 2004-07-02 | 2006-12-21 | Ewing William R | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions |
| CN101532996A (zh) * | 2008-03-10 | 2009-09-16 | 北京德众万全医药科技有限公司 | 一种hplc法分析分离左乙拉西坦的方法 |
| CN103304464A (zh) * | 2013-05-10 | 2013-09-18 | 成都合迅医药技术有限公司 | 一种制备左乙拉西坦的方法 |
| CN105037183A (zh) * | 2015-07-02 | 2015-11-11 | 浙江华海药业股份有限公司 | 一种普瑞巴林杂质的制备方法 |
| WO2017033212A1 (en) * | 2015-08-26 | 2017-03-02 | Actavis Group Ptc Ehf. | Preparation of sacubitril and salt thereof and novel compounds used in the process |
-
2018
- 2018-05-16 CN CN201810468738.9A patent/CN108409592B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0101588A1 (en) * | 1982-08-13 | 1984-02-29 | S.I.P.C.A.M. S.p.A. Società Italiana Prodotti Chimici e per l'Agricoltura Milano | Compositions comprising amino and diamino acid derivatives and use thereof as plant growth stimulants |
| US20050070519A1 (en) * | 2001-12-19 | 2005-03-31 | Schofield Christopher Joseph | Cyclisation process for the preparation of c-2 beta-lactam compounds |
| US20060287242A1 (en) * | 2004-07-02 | 2006-12-21 | Ewing William R | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions |
| CN101532996A (zh) * | 2008-03-10 | 2009-09-16 | 北京德众万全医药科技有限公司 | 一种hplc法分析分离左乙拉西坦的方法 |
| CN103304464A (zh) * | 2013-05-10 | 2013-09-18 | 成都合迅医药技术有限公司 | 一种制备左乙拉西坦的方法 |
| CN105037183A (zh) * | 2015-07-02 | 2015-11-11 | 浙江华海药业股份有限公司 | 一种普瑞巴林杂质的制备方法 |
| WO2017033212A1 (en) * | 2015-08-26 | 2017-03-02 | Actavis Group Ptc Ehf. | Preparation of sacubitril and salt thereof and novel compounds used in the process |
Non-Patent Citations (3)
| Title |
|---|
| DAVID W. KNIGHT等，: ""β-Hydroxypiperidinecarboxylates: additions to the chiral pool from bakers’ yeast reductions of β-ketopiperidinecarboxylates"", 《J. CHEM. SOC., PERKIN TRANS.1》 * |
| REGISTRY，COLUMBUS,OHIO，US REGISTRY[ONLINE]，: "《STN检索报告》", 14 February 2014 * |
| YAHUI FENG等，: ""Development of an Efficient and Scalable Biocatalytic Route to (3R)‑3-Aminoazepane: A Pharmaceutically Important Intermediate"", 《ORG. PROCESS RES. DEV.》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11384050B1 (en) | 2021-02-03 | 2022-07-12 | Vitaworks Ip, Llc | Method for preparing levetiracetam and intermediates thereof |
| WO2022169747A1 (en) * | 2021-02-03 | 2022-08-11 | Vitaworks Ip, Llc | Method for preparing levetiracetam and intermediates thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108409592B (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018102141A4 (en) | Method for preparing Baricitinib | |
| CN101309913B (zh) | 制备地莫匹醇及其衍生物的方法 | |
| WO2022179448A1 (zh) | 一种三氟甲烷硫醇银(i)的合成方法 | |
| CN108409592A (zh) | 一种左乙拉西坦的杂质及其合成方法 | |
| CA2002671C (en) | Process for the production of 4,5-dichloro-6-ethyl-pyrimidine | |
| JP5418526B2 (ja) | ３−（４−テトラヒドロピラニル）−３−オキソプロパン酸アルキル化合物及び４−アシルテトラヒドロピランの製法 | |
| JP2015520750A (ja) | オキセタン−３−イルメタンアミンの製造方法 | |
| JP5001144B2 (ja) | ２−イソプロペニル−５−メチル−４−ヘキセン−１−イル３−メチル−２−ブテノアートの製造方法 | |
| US20130060031A1 (en) | Process for the preparation of highly pure ambrisentan | |
| CN112592306A (zh) | 吡咯啉酮类化合物及其合成方法 | |
| CN111454217A (zh) | 阿普替尼中间体的制备方法 | |
| CN111825593B (zh) | 3-氨基吡咯-2-甲酰胺类化合物的合成方法 | |
| JP3031279B2 (ja) | ２−アルコキシ−６−（トリフルオロメチル）ピリミジン−４−オルの製造方法 | |
| CN109734616B (zh) | 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法 | |
| US11603354B2 (en) | Intermediate compounds and methods | |
| CN109836386B (zh) | 瑞舒伐他汀钙的合成工艺 | |
| JP4039026B2 (ja) | ３−アミノ−２−チオフェンカルボン酸エステルの製法 | |
| JP4280464B2 (ja) | ４−トリフルオロメチルニコチン酸又はその塩の製造方法 | |
| KR100516383B1 (ko) | 디히드로카보스트릴 유도체의 신규 제조방법 | |
| JP3855686B2 (ja) | ３，３−ジアルコキシ−２−ヒドロキシイミノ誘導体及びその製造法 | |
| CN115010754A (zh) | （1-氰基乙基）磷酸二乙酯的制备方法 | |
| US20220242826A1 (en) | Processes and intermediates for the preparation of 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydroisoquinolin-2(1h)-yl]ethenone | |
| JPH0210829B2 (zh) | ||
| CN111471020A (zh) | 一种阿普替尼中间体的制备方法 | |
| JP2023548682A (ja) | Ｌ－フェニルアラニンエステルの新規合成 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |